Compare XBIT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | PYXS |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | 85 | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 82.3M |
| IPO Year | 2015 | 2021 |
| Metric | XBIT | PYXS |
|---|---|---|
| Price | $2.43 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 42.9K | ★ 340.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $0.92 |
| 52 Week High | $3.61 | $5.55 |
| Indicator | XBIT | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 60.11 |
| Support Level | $2.15 | $1.28 |
| Resistance Level | $2.46 | $1.69 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 70.83 | 71.55 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.